Pharmacy World & Science

, Volume 29, Issue 2, pp 58–66 | Cite as

Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes

  • Balázs HankóEmail author
  • Margit Kázmér
  • Péter Kumli
  • Zsuzsanna Hrágyel
  • Antal Samu
  • Zoltán Vincze
  • Romána Zelkó
Research Article


Background: Type 2 diabetes is a complex disorder that requires the patient to pay constant attention to diet, physical activity, glucose monitoring and medication.

Objective: To evaluate the medication, lifestyle adherence and factors associated to these in Type 2 diabetes in Hungarian patients.

Setting: Fourteen community pharmacies in Hungary between March and May 2004.

Method: A questionnaire was given to every tenth Type 2 diabetic patient who presented to one of the 14 pharmacies included in this study with a prescription for oral antidiabetics, oral antidiabetics and insulin or exclusively insulin. For the latter two groups, the prerequisite for inclusion in the study was also that their diabetes had developed after the age of 35 and that at some in their treatment regimen they had taken only oral antidiabetics. These latter two criteria were controlled in the patient's general practitioners' (GP) database. General and diabetes-related data were collected in the questionnaire, and the adherence and lifestyle of the participant were assessed. An adapted and validated Hungarian version of the EQ-5D (EuroQol Group, 1993) quality-of-life questionnaire was also included. Descriptive and χ2 test statistical methods and two sample t-test were used. A significance level of P<0.05 was considered to be significant.

Main outcome measure: Patient self-reported adherence to diet, physical activity, self monitoring of blood glucose, purchasing of drug(s), drug regimen, association of demographic factors, treatment, lifestyle and quality of life on adherence.

Results: Of the 220 questionnaires distributed to diabetic patients, 151 were returned, of which 142 were evaluated (nine did not satisfy the above-mentioned inclusion criteria). With respect to the factors assessed, sub-optimal adherence was assessed for: diet (76.8%), physical activity (33.8%), self-monitoring of blood glucose (81%), drug purchasing (20.4%) and drug taking (52.1%). Smokers comprised 14.8% of the respondents, while 8.5% were heavy drinkers. Fewer than five meals a day were eaten by 46.5% of the patients, and about 43.6% of the patients did not self-monitor blood glucose. The results indicate few significant associations between at least one of the four main areas of adherence (diet, physical activity, purchasing of drug(s), drug regimen) and body mass index, GP consultation frequency, quality-of-life parameters and EQ-5D index.

Conclusion: The adherence of Hungarian Type 2 diabetics in some areas does not reach optimal levels, especially for diet, self-monitoring, drug purchasing and adherence to drug taking.


Adherence Community pharmacies EQ-5D Hungary Type 2 diabetes 



The authors are grateful for the support of the Hungarian Association of Private Pharmacists and the cooperating pharmacists.


  1. 1.
    Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for health care professionals from the American Heart Association. Circulation 1999;100:1134–46PubMedGoogle Scholar
  2. 2.
    Glasgow RE. Compliance to diabetes regimens: conceptualization, complexity and determinants. In: Cramer JA, Spilker B, editor. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991Google Scholar
  3. 3.
    World Health Organization. Report on medication adherence. Geneva: World Health Org; 2003Google Scholar
  4. 4.
    Rubin Richard R. Adherence to pharmacologic therapy in patients with Type 2 diabetes mellitus. Am J Med 2005;118:27S–34SPubMedCrossRefGoogle Scholar
  5. 5.
    Pugh MJ, Anderson J, Pogach LM, Berlowitz DR. Differential adoption of pharmacotherapy recommendations for Type 2 diabetes by generalists and specialists. Med Care Res Rev 2003;60:178–200PubMedCrossRefGoogle Scholar
  6. 6.
    Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CT. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178–83PubMedGoogle Scholar
  7. 7.
    Brown JB, Nichol GA, Glauber HS, Bakst A. Ten year follow up of antidiabetic drug use, non-adherence and mortality in a defined population with type 2 diabetes. Clin Ther 1999;21:1045–57PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson SB. Methodological issues in diabetes research: measuring adherence. Diabetes Care 1992;15:1658–67PubMedGoogle Scholar
  9. 9.
    Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300–6PubMedCrossRefGoogle Scholar
  10. 10.
    Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self management and quality of life. Diabetes Spectrum 2001;14:33–41Google Scholar
  11. 11.
    Cramer Joyce A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24PubMedGoogle Scholar
  12. 12.
    Dezii Christopher M. Persistence with drug therapy: a practical approach using administrative claims data. Managed Care 2001;10:42–5Google Scholar
  13. 13.
    Act LXIII of 1992 on the Protection of Personal Data and the Publicity of Data of Public InterestGoogle Scholar
  14. 14.
    DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200–9PubMedCrossRefGoogle Scholar
  15. 15.
    Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9PubMedCrossRefGoogle Scholar
  16. 16.
    Koopmanschap M. CODE-2 Advisory Board. Coping with Type II diabetes: the patient’s perspective. Diabetologia 2002;45:S18–22PubMedGoogle Scholar
  17. 17.
    Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orvosi Hetilap 2003;144:1667–74PubMedGoogle Scholar
  18. 18.
    Szende A, Molnar L. General population-based quality of life measurements with the EQ-5D questionnaire. Value Health 2000;3:6–29Google Scholar
  19. 19.
    Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998;7:311–22PubMedCrossRefGoogle Scholar
  20. 20.
    Ankri J, Beaufils B, Novella JL, Morrone I, Guillemin F, Jolly D, et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 2003;56:1055–63PubMedCrossRefGoogle Scholar
  21. 21.
    Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore. Qual Life Res 2003;12:87–92PubMedCrossRefGoogle Scholar
  22. 22.
    Granja C, Teixeira-Pinto A, Costa-Pereira A. Quality of life after intensive care-evaluation with EQ-5D questionnaire. Intens Care Med 2002;28:898–907CrossRefGoogle Scholar
  23. 23.
    Burstrom K, Johannesson M, Dideichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621–35PubMedCrossRefGoogle Scholar
  24. 24.
    The MHV Group. The measurement and valuation of health: Final report on the modeling of valuation tariffs. York: Centre for Health Economics, University of York; 1995Google Scholar
  25. 25.
    Martin Bland. An introduction to medical statistics. Oxford: Oxford University Press; 1991Google Scholar
  26. 26.
    Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–73Google Scholar
  27. 27.
    Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-Monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30:112–25PubMedGoogle Scholar
  28. 28.
    Anderson LA. Health-care communication and selected psychosocial correlates of adherence in diabetes management. Diabetes Care 1990;13:66–76Google Scholar
  29. 29.
    Hungarian Central Statistical Office (homepage on the Internet). Counted population 2004. Budapest, Hungarian Central Statistical Office (cited 18 Jul 2004). Available from: http// Scholar
  30. 30.
    Hungarian Gallup Organization (homepage on the Internet). National Health Interview Survey Hungary. Hungarian Gallup Organization (cited 15 Jan 2005). Available from: http// Scholar
  31. 31.
    Shobhana R, Begum R, Snehalatha C, Vijay V, Ramachandran A. Patients’ adherence to diabetes treatment. J Assoc Physicians India 1999;47:1173–75PubMedGoogle Scholar
  32. 32.
    Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with Type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun 2001;6:99–115CrossRefGoogle Scholar
  33. 33.
    Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987;10:563–6PubMedGoogle Scholar
  34. 34.
    Searle MS, Ready AE. Survey of exercise and dietary knowledge and behaviour in persons with Type II diabetes. Can J Public Health 1991;82:344–8PubMedGoogle Scholar
  35. 35.
    Swift CS, Armstrong JE, Beerman KA, Campbell RK, Pond-Smith D. Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes. Diabetes Educ 1995;21:533–40PubMedGoogle Scholar
  36. 36.
    Vincze G, Parthan A. The value of home monitoring kits in diabetes, hypertension, asthma, and oral anticoagulation therapy. J Pharm Pract 2004;17:182–96CrossRefGoogle Scholar
  37. 37.
    Patrick AW, Gill GV, MacFarlane IA, Cullen A, Power E, Wallymahmed M. Home glucose monitoring in Type 2 diabetes: is it a waste of time? Diabetes Med 1994;11:62–5Google Scholar
  38. 38.
    Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice. Br Med J 1997;314:964–7Google Scholar
  39. 39.
    Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 2000;23:477–83PubMedGoogle Scholar
  40. 40.
    Anonymus. Many patients choose not to comply with prescribed medication regimens. Drug Benefit Trends 2004;16:107–8Google Scholar
  41. 41.
    Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411–15PubMedGoogle Scholar
  42. 42.
    Chiechhanowski PS, Katon WJ, Russo JE. Depression and diabetes. Arch Int Med 2000;160:3278–85CrossRefGoogle Scholar
  43. 43.
    Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with Type 2 diabetes mellitus. Clin Ther 2001;23:1311–20PubMedCrossRefGoogle Scholar
  44. 44.
    Dezii Christopher M, Kawabata H, Tran M. Effects of once daily and twice daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South Med J 2002;95: 68–71PubMedGoogle Scholar
  45. 45.
    Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002;19:685–8PubMedCrossRefGoogle Scholar
  46. 46.
    Melikian C, White J, Vanderplas A, Dezii Christopher M, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24: 460–7PubMedCrossRefGoogle Scholar
  47. 47.
    Morningstar BA, Sketirs IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by Type of oral antihyperglyceamic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27: 213–20PubMedCrossRefGoogle Scholar
  48. 48.
    Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015–21PubMedGoogle Scholar
  49. 49.
    Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HGM, et al. Refill compliance in Type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidem Drug Safe 2003;12:121–7CrossRefGoogle Scholar
  50. 50.
    Venturini F, Nichol MB, Sung JCY, Bailey KL, Cody M, McCombs JS. Compliance with sulfanylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281–8PubMedCrossRefGoogle Scholar
  51. 51.
    Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. Aust N Z J Med 1984;14:135–41PubMedGoogle Scholar
  52. 52.
    Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with Type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958–71PubMedCrossRefGoogle Scholar
  53. 53.
    Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in Type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002;132:379–85PubMedGoogle Scholar
  54. 54.
    Johnson KH, Bazargan M, Bing EG. Alcohol consumption and compliance among inner-city minority patients with Type 2 diabetes mellitus. Arch Fam Med 2000;9:964–70PubMedCrossRefGoogle Scholar
  55. 55.
    Wikby A, Hornquist JO, Andersson PO. Background, quality of life and metabolic control in patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1991;13:53–61PubMedCrossRefGoogle Scholar
  56. 56.
    Eiser C, Flynn M, Green E, Havermans T, Kirby R, Sanderman D, et al. Quality of life in young adults with Type 1 diabetes in relation to demographic and disease variables. Diabetes Med 1992;9:375–8CrossRefGoogle Scholar
  57. 57.
    Piette JD, Heisler M, Wagner TH. Problems paying out-of-packet medication costs among older adults with diabetes. Diabetes Care 2004;27:384–91PubMedGoogle Scholar
  58. 58.
    Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054–60PubMedGoogle Scholar
  59. 59.
    Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626–34PubMedCrossRefGoogle Scholar
  60. 60.
    Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract 2005;13:231–40CrossRefGoogle Scholar
  61. 61.
    Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol 2003;112:489–94PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Balázs Hankó
    • 1
    Email author
  • Margit Kázmér
    • 1
  • Péter Kumli
    • 1
  • Zsuzsanna Hrágyel
    • 1
  • Antal Samu
    • 1
  • Zoltán Vincze
    • 1
  • Romána Zelkó
    • 1
  1. 1.University Pharmacy Department of Pharmacy AdministrationSemmelweis UniversityBudapestHungary

Personalised recommendations